Related Experiment Video
Updated: Jun 26, 2025
09:25
The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse
Published on: May 31, 2016
18.7K
Methylphenidate Versus Placebo for Treating Fatigue in Patients With Advanced Cancer: Randomized, Double-Blind,
Patrick Charles Stone1, Ollie Minton2, Alison Richardson3
1Marie Curie Palliative Care Research Department, Division of Psychiatry, University College London (UCL), London, United Kingdom.
Summary
Methylphenidate did not significantly improve cancer-related fatigue in a 6-week trial. The treatment was safe and well-tolerated, showing no increase in adverse events compared to placebo.
Area of Science:
- Palliative Care Medicine
- Oncology
- Pharmacology
Background:
- Cancer-related fatigue is a prevalent and debilitating symptom in patients with advanced cancer.
- Current treatment options for cancer-related fatigue are limited, necessitating research into novel therapeutic agents.
Purpose of the Study:
- To evaluate the efficacy and safety of individually dose-titrated methylphenidate compared to placebo in managing fatigue in palliative care patients with advanced cancer.
Main Methods:
- A randomized, double-blind, placebo-controlled, multicenter trial involving 162 patients with advanced cancer and significant fatigue.
- Patients received either methylphenidate or placebo, with doses titrated over 6 weeks. The primary outcome was measured using the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) scale.
Main Results:
- Methylphenidate did not demonstrate superiority over placebo in improving FACIT-F scores at 6 weeks (P = .186).
- While a nominal improvement in fatigue was observed over 10 weeks, it did not reach clinical significance. A modest reduction in depression scores was noted in the methylphenidate group.
- No significant differences were found in quality of life, mortality, or serious adverse events between the groups.
Conclusions:
- Individually dose-titrated methylphenidate is not superior to placebo for treating fatigue in advanced cancer patients.
- Methylphenidate was found to be safe and well-tolerated in this palliative care population.
